Is there still an open window in metastatic castration resistant prostate cancer immunotherapy horizon?

In recent years, immunotherapy (mainly with immune checkpoint inhibitors directed against CTLA-4 or the PD-1/PD-L1 axis) represents the breakthrough of anticancer therapy for several highly immunogenic tumors (melanoma, non-small cell lung cancer, and renal cell carcinoma).